{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:31:54Z","timestamp":1793680314056,"version":"4.5.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ypmed.2026.108664","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:46:05Z","timestamp":1789602365000},"page":"108664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A scoping review of naltrexone treatment for opioid use disorder: Clinical hurdles and successes"],"prefix":"10.1016","author":[{"given":"Sandra D.","family":"Comer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2026.108664_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108146","article-title":"A systematic review of patients\u2019 and providers\u2019 perspectives of medications for treatment of opioid use disorder","volume":"119","author":"Cioe","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.ypmed.2026.108664_bb0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.ypmed.2026.108664_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112789","article-title":"Extended-release naltrexone versus oral naltrexone for substance use disorders: a systematic review and meta-analysis","volume":"274","author":"Elmosalamy","year":"2025","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2026.108664_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108599","article-title":"Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: differential antagonism by naltrexone","volume":"221","author":"Flynn","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2026.108664_bb0025","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.ypmed.2026.108664_bb0030","article-title":"Sustained-release naltrexone for opioid dependence","volume":"5","author":"Korn\u00f8r","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ypmed.2026.108664_bb0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2026.108664_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12954-024-00994-z","article-title":"High-dose naloxone formulations are not as essential as we thought","volume":"21","author":"Lemen","year":"2024","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.ypmed.2026.108664_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000313336","article-title":"Naltrexone implants compared to methadone: outcomes six months after prison release","volume":"16","author":"Lobmaier","year":"2010","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.ypmed.2026.108664_bb0050","first-page":"1385","article-title":"Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers","volume":"24","author":"McCaul","year":"2000","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.ypmed.2026.108664_bb0055","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.bjp.0703954","article-title":"Nociceptin inhibits cough in the guinea-pig by activation of ORL1 receptors","volume":"132","author":"McLeod","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ypmed.2026.108664_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2025.104805","article-title":"Barriers to accessing medications for opioid use disorder among rural individuals","volume":"140","author":"Morenz","year":"2025","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.ypmed.2026.108664_bb0065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamapediatrics.2021.4606","article-title":"Access to medications for opioid use disorder and associated factors among adolescents and young adults: a systematic review","volume":"176","author":"Pilarinos","year":"2022","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.ypmed.2026.108664_bb0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1176\/ajp.131.6.646","article-title":"Studies of EN-1639A (naltrexone): a new narcotic antagonist","volume":"131","author":"Resnick","year":"1974","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ypmed.2026.108664_bb0075","article-title":"Receipt of medications for opioid use disorder among rural and urban veterans health administration patients","volume":"14","author":"Reynolds","year":"2025","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.ypmed.2026.108664_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0376-8716(85)90066-3","article-title":"Nalbuphine","volume":"14","author":"Schmidt","year":"1985","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2026.108664_bb0085","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ypmed.2026.108664_bb0090","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/00952997509005661","article-title":"Naltrexone pharmacology, pharmacokinetics, and metabolism: current status","volume":"2","author":"Verebey","year":"1975","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.ypmed.2026.108664_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a Cascade of care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"Am. J. Drug Alcohol Abuse"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743526001702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743526001702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:17:48Z","timestamp":1790687868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743526001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"alternative-id":["S0091743526001702"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2026.108664","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A scoping review of naltrexone treatment for opioid use disorder: Clinical hurdles and successes","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2026.108664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108664"}}